Table 1. Summary of drug concentrations in key anatomic compartments on Day 7, immediately after pod-IVR removal (six participants in each group).
CVF, cervicovaginal fluid; VT, vaginal tissue; RF, rectal fluid. Measurements outside of the analytical ranges were not included in the analysis.
| Pod-IVR Typea | |||
|---|---|---|---|
| Analyte, matrix | TDF | TDF-FTC | TDF-FTC-MVC |
| Total TFV,b CVF, ng mg-1 | 51.3 (34.8–61.5) | 40.8 (28.9–49.1) | 67.4 (43.4–72.1) |
| FTC, CVF, ng mg-1 | 1,458 (881–2,073) | 839 (818–1,572) | |
| MVC, CVF, ng mg-1 | 367 (224–489) | ||
| TFV, VT c, ng mg-1 | 8.4 (4.7–11.2) | 5.1 (0.77–10.1) | 5.1 (3.3–9.7) |
| FTC, VT c, ng mg-1 | 74.5 (11.6–193) | 104 (63.7–302) | |
| MVC, VT c, ng mg-1 | 142 (82.5–212)d | ||
| TFV, RF, ng mg-1 | 0.62 (0.30–0.81)e | 1.11 (0.36–2.15) | 0.004f |
| FTC, RF, ng mg-1 | 20.3 (14.0–28.9) | 0.11 (0.04–0.22)g | |
| MVC, RF, ng mg-1 | 0.84 (0.32–1.10) | ||
aMedian (Interquartile range, 25th to 75th percentile).
bMolar sum of paired TDF and TFV concentrations, reported as TFV.
cUsed with permission [9]
d33% of samples above the analytical quantification limit.
e83% of samples were above the analytical LLQ.
fOnly one sample was above the analytical LLQ.
g67% of samples were above the analytical LLQ.